Quanterix Corporation announced financial results for the first quarter of 2022, with revenue in line with expectations but gross margin falling short. The company is implementing changes to improve gross margins.
Q1 revenue was in line with expectations and full-year goals.
Gross margin fell well short of expectations.
Implementing specific changes to inventory management and quality processes.
Focus on scaling with quality, innovation, and ability to translate ultra-sensitive biomarker detection.
Quanterix is focused on scaling with quality, innovation, and translating ultra-sensitive biomarker detection to help researchers and pharmaceutical companies drive earlier disease detection, better prognoses, and enhanced treatment methods.